Rating Change
Chardan Capital reiterated its Buy rating on Agenus Inc. (NASDAQ:AGEN) on October 05, 2026.
Chardan Capital reiterated its Buy rating on Agenus Inc. (NASDAQ:AGEN) on October 05, 2026.

At publication ·
Agenus Inc. (NASDAQ:AGEN) · reiterate
At a glance
Chardan Capital reiterated its Buy rating on Agenus Inc. (NASDAQ:AGEN) on October 05, 2026.
Agenus Inc. operates in the Healthcare sector. The stock currently trades at $8.40 with a market capitalization of $113.2M.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Agenus Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 05, 2026 | Chardan Capital | Buy | N/A |
| Sep 28, 2026 | Rodman & Renshaw | Buy | N/A |
| Sep 18, 2026 | Chardan Capital | Buy | N/A |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 30, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View AGEN Stock Page
A rating of Buy from Chardan Capital reflects the analyst's outlook on Agenus Inc. (NASDAQ:AGEN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AGEN forecast page.
Current market data
NASDAQ · AGEN
$8.73
Up: +$0.37 · +4.43%
Live quote updated
Keep reading